OSE Immunotherapeutics (XPAR:OSE) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


XPAR:OSE OSE Immunotherapeutics SA XPAR:OSE
53 GF Score
Price €3.05
GF Value €1.49
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is OSE Immunotherapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

OSE Immunotherapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

XPAR:OSE vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, OSE Immunotherapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OSE Immunotherapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OSE Immunotherapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where OSE Immunotherapeutics's Margin of Safety % (DCF FCF Based) falls into.


XPAR:OSE
53GF Score
OSE Immunotherapeutics SA XPAR:OSE
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is OSE Immunotherapeutics (XPAR:OSE) Overvalued in 2026?

Based on GuruFocus' analysis, OSE Immunotherapeutics stock appears to be overvalued. The current stock price of €3.05 is trading 104.7% above its estimated GF Value™ of €1.49. GuruFocus considers OSE Immunotherapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:OSE:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €1.49 vs. price of €3.05 (104.7% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the XPAR:OSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OSE Immunotherapeutics Business Description

Other Exchanges ORPOF:USA0RAD:UK6OP:Germany
Address 22, Boulevard Benoni Goullin, Nantes, FRA, 44200
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.
53GF Score

Get the complete analysis for XPAR:OSE

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.05
Price
€1.49
GF Value